| Objective To evaluate the clinical characteristics in female patients with coronary heart disease treated with percutaneous coronary intervention (PCI) and the protective influence ofβ-adrenergic blocker therapy on patients before PCI.Methods We recruited 266 consecutive subjects with coronary heart disease (75 females,191 males) treated withβ-adrenergic blocker before and after PCI.50 consecutive subjects with coronary heart disease were also included, whereas, those were not receivedβ-adrenergic blocker therapy. Data were examined for gender-specific differences regarding patients'characteristics, angiographic findings, procedural details, and major adverse cardiac events(MACE) during 1 year follow-up periods after PCI. Furthermore, blood samples were collected from each subject of F1 and F2 to determine the CK-MB, TNT, E and NE.Result Compared with male subjects group, multi-vessel lesions was significantly higher in female subjects group (P<0.05). Furthermore, women had significantly higher post-PCI complications such as bleeding events, recurrent angina, renal failure and unadjusted mortality (P all<0.05). The E, NE, CK-MB and TNT significantly increased before and after PCI in the female coronary heart disease subjects withoutβ-adrenergic blocker therapy than those treated withβ-adrenergic blocker (P<0.05,<0.01).Overall, the incidence of MACE and postoperative bleeding events and mortality were significantly increased in female subjects withoutβ-adrenergic blocker therapy after PCI and during 1 year follow-up periods (P all<0.05)Conclusion Women with coronary heart disease underwent PCI therapy had severer coronary artery lesions,and the incidence of post-PCI complications and mortality were higher than men. Pretreatment withβ-adrenergic blocker can reduce the occurrence of PCI complications and long-term mortality, and has protective effect on female patients. |
PDF Full Text Request